

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
1 November 2001 (01.11.2001)

PCT

(10) International Publication Number  
WO 01/80898 A1(51) International Patent Classification<sup>7</sup>: A61K 47/00

(74) Agent: WATKINS, Marcella, D.; Conley, Rose &amp; Tayon, P.C., P.O. Box 3267, Houston, TX 77253-3267 (US).

(21) International Application Number: PCT/US01/13445

(22) International Filing Date: 27 April 2001 (27.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/199,970 27 April 2000 (27.04.2000) US

(71) Applicant (for all designated States except US): WM. MARSH RICE UNIVERSITY [US/US]; 6100 Main Street, Houston, TX 77005 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): WILSON, Lon, J. [US/US]; 7725 Windward Passage, Houston, TX 77072 (US). SAGMAN, Uri [CA/CA]; 13 Old Forest Hill Road, Toronto, Ontario M5P 2P6 (CA). GONZALES, Kelly, A. [US/US]; - (US). PRITZKER, Kenneth [US/US]; - (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FULLERENE-BASED DRUGS TARGETED TO BONE



(57) Abstract: A method for providing bone therapy in a patient in need of bone therapy comprises administering to the patient a pharmaceutically effective amount of a compound comprising a biologically inert carrier, a bone vector, and a therapeutic agent. The bone vector preferably comprises a bisphosphonate, the carrier preferably comprises a fullerene, and more preferably C<sub>60</sub>, the therapeutic agent preferably comprises fluoride.

**Fullerene-Based Drugs Targeted to Bone**  
**CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application claims the benefit of U.S. Provisional Application Serial No. 60/199,970 filed April 27, 2000, which is incorporated herein by reference.

**5 FIELD OF THE INVENTION**

The present invention relates generally to the delivery of therapeutic compounds to bone and more particularly to the use of fullerene molecules to mitigate the toxicity of bone-therapeutic agents. Still more particularly, the present invention relates to the use of fullerenes in conjunction with bone-vectoring compounds and bone-therapeutic agents to yield a bone-targeted, non-toxic bone-therapeutic agent.

## BACKGROUND OF THE INVENTION

Bone is the hard form of connective tissue that makes up most of the skeleton; it consists of an organic component, the cells and matrix, and an inorganic, or mineral component. The matrix contains a framework of collagenous fibers, mainly infused with the mineral component, calcium, which makes bone rigid and strong. Tiny fluid-containing channels, called canaliculi, cross the mineralized bone, facilitating the transfer of calcium from the bone interior to exterior.

There are a total of 206 bones in the human skeleton. Bone serves as a structural frame to support the body; it enables movement by providing a point of attachment for the muscles and by serving as a system of levers; it protects the brain, spinal cord, and the soft internal organs; it houses the blood-forming system (red bone marrow); and it acts as a reservoir for the mineral calcium, which is vital to many body processes.

Living bone is continuously recycled by the processes of bone formation and resorption. During an animal's growth years, bone formation exceeds resorption and the skeletal mass increases. In humans, bone mass reaches a peak between ages 20 and 30

years. After that time, the rate of formation and resorption stabilize the bone mass until age 35 to 40 years, at which time resorption begins to exceed formation, and the total mass slowly decreases. The process of bone turnover in adults is known as remodeling. Up to 15 per cent of the total bone mass turns over every year in the remodeling process.

5           Two major cell types make up bone and are responsible for the remodeling process (ossification): osteoclasts and osteoblasts. Osteoclasts absorb and remove mineralized bone, releasing calcium and phosphate. Osteoblasts assimilate calcium and phosphate to slowly produce crystals, or mineralized bone. As the mineralized bone accumulates and surrounds the osteoblast, that cell slows its activity and becomes an interior osteocyte.

10           Between the areas of osteoclastic and osteoblastic activity is a cement line containing bone matrix material, which delineates the zones of resorption and new bone formation. Bone formation takes place in areas where bone undergoes the greatest stress. Therefore, a bone that is underutilized, such as a leg that is immobilized, is prone to resorption.

15           Bone remodeling not only alters the architecture of the bone, it also enables the body to regulate the levels of calcium ions in the blood and interstitial fluid. These calcium levels must remain within a fairly narrow range in order to ensure the proper functioning of nerve transmission, the integrity and permeability of cellular membranes, and the ability of the blood to clot. Bone contains about 99 percent of the body's calcium. When fluid calcium  
20   levels fall too low, parathyroid hormone stimulates osteoclast activity (causing increased bone resorption) and the subsequent release of calcium into the bloodstream. When fluid calcium levels rise excessively, the hormone calcitonin inhibits resorption (acting against the parathyroid hormone), thereby restricting the release of calcium from the bones. It is necessary to have a healthy intake of calcium to maintain the body's calcium reserve;  
25   otherwise, the calcium levels in the body become dependent on the resorption of bone

tissue. Vitamin D is also essential, as it makes possible the body's use of ingested calcium. Estrogen also inhibits bone resorption.

The susceptibility of bone to disease alters with age. Children tend to suffer from abnormal bone development. Young adults are prone to rheumatoid arthritis and spinal  
5 difficulties, such as scoliosis. The elderly are vulnerable to metabolic disorders that affect the composition of bone, as well as to osteoarthritis and other joint disorders and to circulatory problems that affect bone health.

Many bone diseases are related to the composition and scale of bone tissue. For example, when a bone has much more bone tissue than average, it is termed osteosclerosis;  
10 when there is less, it is called osteopenia. If bone suffers from a lack of mineral content, it is called rickets in children and osteomalacia in adults. The afflicted bones become malleable and vulnerable to deformities. In children, this condition is often the result of vitamin D deficiency. Of all bone diseases, osteoporosis, a generalized osteopenia, is the most common. This disease primarily affects the aged and is more serious in women than men.  
15 Osteoporosis is responsible for many of the fractures encountered by the elderly. Another disease that often afflicts the elderly is Paget's disease, characterized by bone deformity and calcium imbalance.

Likewise, bone cells can be killed by a lack of blood supply; this tissue death is termed necrosis or osteonecrosis. It can be brought on by injury, the blockage of an artery,  
20 circulatory problems, the administration of corticosteroid hormones for the treatment of another affliction, or by a disease of the metabolic system. Osteomyelitis refers to a bone infection, which can be acquired through an open wound, or from an infection elsewhere in the body. Tumors can also develop in bone tissue. Congenital bone diseases refer to abnormalities which are present at birth; some are genetically transferred but most occur  
25 due to problems during pregnancy or delivery. Lastly, bone fractures are the result of a

force greater than the strength and resistance of the bone. Age and disease are factors that determine whether a given force will cause a fracture.

The conditions and factors listed above can cause undesired bone loss or a need to replace lost bone through enhanced bone growth. Hence, compositions that mitigate bone  
5 loss and/or encourage bone growth are the subject of ongoing research.

For example, various chemical/hormonal treatments have been tried as methods for treating bone disease. Hormones such as estrogen have shown to promote bone growth. Unfortunately, because estrogens have been linked to cancer and other undesirable side effects, they are not widely prescribed for bone therapy.

10 One recently approved treatment for bone disease is a class of chemicals known as bisphosphonates. Bisphosphonates bind to bone, slowing osteoclasts and allowing new bone to be formed. However, because this effect is temporary, bone mass is not substantially increased in the long term. Because new bone is not formed, bones are left weakened and prone to later injury. Hence, bisphosphonates alone are not entirely  
15 satisfactory. For all of the foregoing reasons, there remains a need for a suitable compound that inhibits bone resorption and promotes new bone formation so as to produce a net bone gain without adversely affecting the patient.

#### SUMMARY OF THE INVENTION

The present invention provides a non-toxic, biologically active composition that is  
20 capable of encouraging bone growth while simultaneously inhibiting bone resorption, so as to produce a net bone gain. A preferred embodiment is a bimodal fullerene-based compound that includes a bone-targeting ligand and a bone growth enhancing ligand. In a particularly preferred embodiment, the composition comprises fullerene molecules, sometimes referred to as "buckyballs," conjugated with both an osteogenic or  
25 osteoinductive agent and a bisphosphonate.

## BRIEF DESCRIPTION OF THE FIGURES

A better understanding of the present invention can be obtained when the following detailed description of the preferred embodiment is considered in conjunction with the following drawings, wherein:

Figure 1 illustrates a typical bisphosphonate;

Figure 2 is an example of a water-solubilized fullerene suitable for use in the present invention;

Figure 3 is an example of a water-solubilized bone-targeted fullerene suitable for use in the present invention;

Figure 4 is an example of a water-solubilized bone-targeted fullerene including a therapeutic agent in accordance with one embodiment of the present invention;

Figure 5 is a plot of titrant volume added as a function of time during constant composition hap crystal growth inhibition experiments with  $C_{60}(OH)_{30}$ ;

Figure 6 is a plot of titrant volume added as a function of time during constant composition hap crystal growth inhibition experiments with  $C_{60}(OH)_{16}AMBP$ ;

Figure 7 is a plot of the rate of HAP crystal growth in the presence of  $C_{60}(OH)_{30}$  and  $C_{60}(OH)_{16}AMBP$  as a function of additive concentration; and

Figure 8 is a plot of  $R_0/R$  versus concentration for  $C_{60}(OH)_{30}$  and  $C_{60}(OH)_{16}AMBP$ .

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention employs fullerene- or metallofullerene-based materials as diagnostic and therapeutic drugs because they are relatively non-toxic, non-metabolizable, and capable of in vivo delivery diagnostic and/or therapeutic agents. Additionally, with the aid of targeting agents, the present fullerene- and metallofullerene-based materials are

capable of being selectively delivered to specific tissue upon demand. A preferred embodiment is a bimodal fullerene-based compound that includes a bone-targeting ligand and a bone growth enhancing ligand.

The present invention comprises three main components: (1) a vector, (2) a carrier  
5 and (3) a therapeutic/diagnostic agent. Preferred embodiments of each of these components are discussed in detail below.

#### Vector

A vector is defined herein as something that targets a specific tissue, in this case bone. In preferred embodiments, bisphosphonates are used as bone-targeting vectors.  
10 Bisphosphonates are compounds characterized by two C-P bonds. A representative bisphosphonate is shown in Figure 1. All bisphosphonates act in a similar manner on bone: they bind permanently to mineralized bone surfaces and inhibit subsequent osteoclastic activity, namely the removal of bone during the process of bone remodeling. Because they reduce the amount of bone tissue degraded during the remodeling cycle, they are sometimes  
15 referred to as "antiresorptive agents." The application of bisphosphonates usually reduces bone loss and, correspondingly, the risk of broken bones, and sometime increases bone mass.

As a group, the bisphosphonates offer several advantages over estrogens in treating osteoporosis. They are bone-tissue specific, have minimal side effects (e.g. nausea,  
20 abdominal pain and loose bowel movements), cause no known risk of carcinogenesis, and have antiresorptive efficacy that is equivalent to or greater than estrogens. There is some evidence that the use of bisphosphonates can cause a reduction in incident vertebral fractures.

#### Carrier

A carrier is defined herein as something that transports other things, in this case a vector and at least one therapeutic/diagnostic agent. Fullerene molecules, sometimes referred to as "buckyballs," are preferred carriers because they are relatively non-toxic, suitably sized for in vivo applications, biologically inert, and can be made water soluble.

5 Additionally, because of the large number of pi-bonds in fullerenes, they can easily be attached to other molecules, making them an ideal vehicle for transporting other substances. Still further, it is believed that the spherical shape of certain fullerenes provides a versatile scaffold to which ligands can be attached in a variety of substantially controllable and selectable configurations.

10  $C_{60}$ , illustrated in Figure 2, is an example of a fullerene suitable for use in the present invention. Other suitable fullerenes include but are not limited to:  $C_{70}$ ,  $C_{80}$ , and their derivatives, endofullerenes, nanotubes, and higher carbon-number fullerenes. While fullerene molecules are acceptably non-toxic, their use in vivo is limited by their hydrophobicity. Fullerenes are known to be rendered less hydrophobic by the addition of  
15 hydroxyl or carboxylic acid groups. In general, 12-16 hydroxyl groups or six carboxyl groups are needed to adequately solubilize  $C_{60}$  and related fullerene molecules. Figure 3 illustrates an exemplary bisphosphonated hydroxylated fullerene capable of functioning as a bone-targeted carrier.

In a preferred embodiment, vectors and therapeutic/diagnostic agents are externally  
20 bound the carrier. In some embodiments, however, it is contemplated that fullerene cages may contain such substances, i.e. therapeutic and/or diagnostic agents. For instance, a radionuclide-containing fullerene derivative could be successfully vectored to diseased sites in bone so as to provide tissue-specific radiation therapy.

#### Therapeutic and/or Diagnostic Agent

A therapeutic agent is defined herein as a compound that is used to treat disease or alter a medical condition. Because the number of diseases and injuries in bone is large, many therapeutic agents are contemplated for use in the present invention. Additionally, because the therapeutic agents are attached to a carrier, substances that may be too toxic to  
5 be transported in the body in free form can be used in the present invention.

For example, fluoride anion ( $F^-$ ) is known to be an active therapeutic agent for treatment of osteoporosis. While  $F^-$  is too toxic to be administered in free form (e.g. injecting NaF in aqueous solution intravenously),  $F^-$  may be incorporated into a delivery system that releases the agent at the bony site and avoids early, potentially harmful, release  
10 in the body before reaching the bony site. Other suitable therapeutic agents may include, but are not limited to: antioxidants, photodynamic therapeutic agents, and biologically derived agents, such as collagen-derived proteins and bone growth factor (bfg).

Alternatively, the bone-vectored fullerenes of the present invention can be used in conjunction with diagnostic agents. Suitable diagnostic agents that can be bound to  
15 fullerenes include but are not limited to: magnetic resonance imaging (MRI) contrast agents such as paramagnetic lanthanide or transition metal ion complexes, radiotracers/radioactive metal ions, and the like.

Bone tissue is an especially appealing target for vectored pharmaceuticals because its primary inorganic component, hydroxyapatite (HAP), offers a multitude of binding sites  
20 for structurally suitable compounds. Compounds with functional groups such as hydroxyls and carboxylic and phosphonic acids are capable of forming ionic and hydrogen bonds to the mineral portion of bone. The interactions between a bone-vectored compound and the mineralized tissue may be modeled in vitro using HAP crystal growth inhibition studies, whereby compounds with high affinity for HAP bind to the surface of the crystals at kinks  
25 and dislocations, blocking crystallization. Using carefully designed experiments, the extent

of crystal growth inhibition by a bone-vectored compound can then be used to estimate the compound's affinity for bone tissue in vivo.

Crystal growth inhibition technology is especially important because bone-vectored compounds typically target areas of bone that are undergoing formation and resorption processes (remodeling). The vectored compounds are attracted to the active growth sites of HAP, and thus bind in greatest concentration to the metabolically-active portions of bone. Where bone tissue is diseased, a high rate of bone metabolism exists, and this activity attracts suitably-derivatized compounds to the diseased site.

Figure 4 illustrates one preferred embodiment of the present invention. An alendronate (a bisphosphonate) is the vector or targeting agent, C<sub>60</sub> is the carrier, and fluoride is the therapeutic agent. It will be understood that modifications can be made to composition of the ligands and the carrier, and the relative amounts of each can be varied, so long as each ligand and the carrier can be combined to give an effective, bone-targeted, bone-therapeutic compound. Because the compounds of the present invention are highly tissue-specific, the dose level required for treatment is relatively low. This, in turn, reduces treatment costs and potential harm to non-diseased tissues. Heretofore, no tissue-vectored fullerene derivatives have been reported. The following Example is intended to be illustrative only and are not intended to limit the scope of the present invention.

#### EXAMPLE

A bisphosphonate-C<sub>60</sub> derivative (C<sub>60</sub>(OH)<sub>16</sub>AMBP) is targeted to mineralized bone in vitro. This example does not contain a therapeutic agent, because it is meant to illustrate that fullerene-based materials are capable of being selectively delivered to specific tissue. One or more known therapeutic(s) to a fullerene-based material for bone stimulation may be added by methods known in the art.

#### 25 Materials

Reagent grade solvents and electrolytes (Fisher) were used without purification unless stated otherwise. Anhydrous solvents were obtained by distillation from appropriate drying agents under inert atmosphere. Petroleum ether and bromobenzene were each pre-dried with NaSO<sub>4</sub> and then refluxed over and distilled from sodium. Benzene, toluene, and ethyl ether were each pre-dried with CaCl<sub>2</sub> and then refluxed over and distilled from sodium in the presence of sodium benzophenone ketyl. Chloroform, stabilized with 0.75% ethanol, was used as received. Triethylamine was distilled from KOH under inert atmosphere.

Silica gel (Aldrich, grade 62, 60-200 mesh, 150 Å) was activated at 130 °C for a minimum of 12 hours before use. Sephadex G-25 (Aldrich, 20-80 µ) was equilibrated in DI H<sub>2</sub>O for 24 h at room temperature prior to use.

#### Physical and Spectroscopic Methods

Unless otherwise noted, residual solvent signals were used for spectral reference in the <sup>13</sup>C and <sup>1</sup>H NMR spectra (DMSO-d<sub>6</sub>, 2.50 and 39.1 ppm; CDCl<sub>3</sub>, 7.26 and 77.0 ppm; D<sub>2</sub>O, 4.70 ppm). Phosphoric acid (85%, 0 ppm) was used as an external reference for <sup>31</sup>P NMR spectra. Signals that were shifted upfield from H<sub>3</sub>PO<sub>4</sub> were assigned positive values; signals downfield from H<sub>3</sub>PO<sub>4</sub> were assigned negative values. For each set of phosphorus NMR data, the upfield or downfield shift is stated for clarity.

Mass spectra were measured on a Finnigan MAT 95 GC-MS analyzer using electron ionization (EI, 70 eV) or atmospheric pressure chemical ionization (APCI). High resolution APCI peak matching spectra were collected using Gramocidin S as the peak reference at 1141.71376 amu in 50/50 CHCl<sub>3</sub>/MeOH.

Elemental analyses were obtained commercially from Galbraith Laboratories, Inc., Knoxville, Tennessee.

#### 25 Materials and Methods for HAP Crystal Growth Inhibition Studies

Hydroxyapatite seed crystals were prepared from calcium nitrate and potassium dihydrogen phosphate, as detailed elsewhere. The specific surface area,  $34.9 \text{ m}^2 \text{ g}^{-1}$ , was determined by BET nitrogen adsorption using a 30/70  $\text{N}_2/\text{He}$  mixture (Monosorb, Quantachrome Corp). HAP crystals in the form of a suspension in water ( $41.8 \text{ g L}^{-1}$ ) were  
5 used for the crystal growth experiments.

Solutions were prepared using triply distilled carbon dioxide-free water and filtered before use through washed  $0.22 \text{ }\mu\text{m}$  filters (Millipore, Bedford, MA). Calcium concentrations were determined either complexometrically by EDTA titration with Eriochrome Black-T as indicator, or by atomic absorption (Perkin-Elmer, model 3100,  
10 Norwich, CT). Carbon dioxide-free potassium hydroxide solutions were prepared from washed Reagent grade pellets in a nitrogen atmosphere.

Crystal growth experiments were made in magnetically-stirred water-jacketed Pyrex vessels at  $37.0 \pm 0.05 \text{ }^\circ\text{C}$  with ionic strength,  $I = 0.15 \text{ mol L}^{-1}$ , adjusted by the addition of sodium chloride. Supersaturated solutions were prepared by introducing calcium chloride  
15 solution, followed by potassium dihydrogen phosphate solution. The pH was adjusted to the required value by the slow addition of potassium hydroxide solutions. During the reactions, carbon dioxide was excluded by bubbling with presaturated nitrogen gas. After equilibration,  $0.5 \text{ mL}$  of the HAP slurry was introduced to initiate the reaction. Since the nucleation and growth of crystals consume solution lattice ions, the lowering of pH was  
20 used to trigger the addition of two titrant solutions that served to maintain constant the pH, the concentrations of calcium and phosphate and the ionic strength of the solution. A glass electrode (Orion, model 9101), standardized using two NBS buffer solutions at  $\text{pH} = 7.386$  and  $4.028$  at  $37 \text{ }^\circ\text{C}$ , was used to control titrant addition through a potentiostat. The total calcium concentration in all experiments was  $6.00 \times 10^{-4} \text{ mol L}^{-1}$  with a calcium/phosphate  
25 molar ratio of 1.67, so as to achieve a supersaturation with respect to HAP of  $\sigma = 5.55$  (as

defined in Eq. (1)), as computed from mass balance, proton dissociation, electroneutrality, and equilibrium expressions involving calcium and phosphate species.

$$\sigma = S - 1 = [IP/K_{SO}]^{1/v} - 1 \quad (1)$$

In Eq. (1),  $v$  is the number of ions per formula unit of precipitating phase and  $IP$  and  $K_{SO}$  are, respectively, the ionic and solubility products of HAP. The addition of the fullerene derivatives at micromolar levels to the reaction solutions did not affect the established supersaturation.

During the reactions, samples were withdrawn periodically, filtered (0.22  $\mu$ m Millipore filter) and analyzed for calcium by atomic absorption and for phosphate spectrophotometrically (Varian, Cary 210) as the phosphovanadomolybdate complex in order to verify the constancy of the solution composition. Solid phases were examined by X-ray powder diffraction, XRD, (Siemens Nicolet/Nic spectrometer, CuK radiation with Ni filter = 1.540; 2  $\theta$  from 30 to 450), by scanning electron microscopy (SEM at 20 kV; JEOL JSM-5300, Noran Instrumental Inc. Middleton, WI) and by diffuse reflectance infrared fourier transform spectroscopy (FTIR, Perkin Elmer 1760X FT-IR spectrometer). Plots of mineralization were calculated from plots of titrant volumes as a function of time as described previously.

In order to investigate the uptake of fullerene derivatives by HAP surfaces, an equilibrium adsorption experiment was performed in which 0.0209 g of HAP in its saturated solution was equilibrated with various concentrations of these additives. A UV-visible spectrophotometer (Perkin-Elmer model 3100) was used for the analysis of fullerene derivative concentrations. Since the  $\zeta$ -potential of HAP surfaces was markedly influenced by the presence of the additives, this parameter was used as an indication of the extent of adsorption. The  $\zeta$ -potential of HAP surfaces for the same suspensions in the presence of these additives was measured using a Malvern Zetasizer IIc (Malvern, England).

### Syntheses

#### 1,2-dihydro-1,2-methanofullerene[60]-61-carboxylic acid, C<sub>60</sub>-CHCOOH

1,2-Dihydro-1,2-methanofullerene[60]-61-carboxylic acid was synthesized according to the procedure by Isaacs and Diederich.

#### 5 Tetraethyl Ethenylidenebisphosphonate

In a typical synthesis, paraformaldehyde (2.60 g, 86.7 mmol) and diethylamine (1.79 mL, 1.27 g, 17.4 mmol) were combined in MeOH (25 mL) with gentle warming to aid dissolution. The mixture was then cooled to room temperature and 5.0 g (17.3 mmol) tetraethyl methylenediphosphonate was added with stirring. The reaction was refluxed for  
10 24 hours under atmospheric conditions and then diluted with 25 mL MeOH and concentrated under vacuum at 35 °C. Toluene (50 mL) was added to the flask and the contents were again concentrated under vacuum at 35 °C. This step was repeated a second time to ensure that all of the MeOH had been removed. The intermediate (tetraethyl 2-methoxyethylenebisphosphonate) was then placed under vacuum at room temperature for 3  
15 h. <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 4.15 (m, 8 H), 3.84 (td, 2 H, JP-H=16.3, JH-H=5.4), 3.33 (s, 3 H), 2.65 (tt, 1 H, JP-H=23.8, JH-H=5.4), 1.30 (t, 12 H, J=7.0).

The reaction flask was attached to a septum-capped soxlet extractor containing 4 Å molecular sieves and the entire system was flushed with Ar for 15 minutes. Approximately 125 mL anhydrous toluene was then added through the condenser. p-Toluenesulfonic acid  
20 monohydrate (0.20 g, 1.1 mmol) was added under Ar sparge and the flask was wrapped with aluminum foil. The reaction was refluxed under inert atmosphere for 14 h. After solvent removal, the remaining light yellow oil was redissolved in CHCl<sub>3</sub>, washed with three 50 mL portions of DI H<sub>2</sub>O, and dried over MgSO<sub>4</sub>. The CHCl<sub>3</sub> was then removed, leaving a yellow oil that distilled over at 139 °C/1 torr as a colorless liquid. An analytically  
25 pure sample was prepared by column chromatography on SiO<sub>2</sub> with 50:50 hexanes/acetone

eluent. Yield: 4.0 g, 77%. <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): 6.96 (distorted dd, JP-H=37.6, JP-H=34.1), 4.14 (m, 8H), 1.33 (t, JH-H=7.1, 12H). <sup>13</sup>C NMR (250 MHz, CDCl<sub>3</sub>, TMS ref.): 149.28, 131.80 (t, JP-C=166.5), 62.60 (t, JP-C=2.8), 16.20 (t, JP-C=3.3). <sup>31</sup>P NMR (250 MHz, CDCl<sub>3</sub>): 13.73 ppm downfield from H<sub>3</sub>PO<sub>4</sub>. IR (neat): 2984 (C-H), 2935 (C-H), 2910 (C-H), 1636 (C=C), 1251, (P=O), 1024 (C-O), 974 (P-C-P bend), 803 cm<sup>-1</sup> (P-O).

#### Benzylidene Glycine Ethyl Ester

In a typical synthesis, the hydrochloride salt of glycine ethyl ester (15.0 g, 107.5 mmol) was dissolved in 125 mL CH<sub>2</sub>Cl<sub>2</sub>. Treatment with freshly distilled NEt<sub>3</sub> (21.8 g, 30 mL, 215.8 mmol) resulted in the formation of a small amount of white precipitate. Benzaldehyde (7.60 g, 7.28 mL, 71.6 mmol) was then added to the reaction at room temperature followed by 6 g MgSO<sub>4</sub> to remove the water by-product. After 10 h stirring, the solution was filtered and reduced under vacuum to give a yellow oil. This compound was dissolved in 100 mL Et<sub>2</sub>O, washed with sat. aq. NaCl (6 x 50 mL) and dried (MgSO<sub>4</sub>). Solvent removal under vacuum at 25 °C gave a light yellow oil that was used without further purification. The compound was stored at 10 °C. Yield: 13.42 g, 98%. <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>, TMS ref.): 8.30 (s, 1 H), 7.78 (m, 2 H), 7.42 (m, 3 H), 4.40 (s, 2 H), 4.24 (q, 2 H, J=7.1), 1.31 ppm (t, 3 H, J=7.1). <sup>13</sup>C NMR (250 MHz, CDCl<sub>3</sub>): 169.99, 165.27, 135.45, 131.07, 128.46, 128.35, 61.94, 60.94, 14.07 ppm. IR (neat): 3063 (Ar C-H), 3029 (Ar C-H), 2983 (C-H), 2938 (C-H), 2975 (C-H), 2903 (C-H), 2854 (C-H), 1735 (C=O), 1646 (C=N), 1200 (C-O), 1027 (C-O), 759 (Ar-H out-of-plane), 694 cm<sup>-1</sup> (Ar-H out-of-plane).

#### Ethyl N-Benzylidene-2-amino-4,4-bis(diethoxyphosphoryl)butyrate

In a typical synthesis, benzylidene glycine ethyl ester (1.91 g, 10.0 mmol) was added to a solution of NaOEt (1 mmol) in 20 mL of fresh absolute EtOH at -8 °C (ice-salt bath). Tetraethyl ethenylidenebisphosphonate (3.00 g, 10.0 mmol) was added drop-wise

over 3 minutes with vigorous stirring. The reaction was stirred for 30 min at 25 °C and then neutralized with sat. aq. NH<sub>4</sub>Cl (ca. 3 mL). Removal of the EtOH (ca. 25 °C) at reduced pressure left a paste-like residue that was extracted with CHCl<sub>3</sub> (3 x 20 mL). The organic fraction was dried over MgSO<sub>4</sub>, filtered and evaporated at reduced pressure to give a light yellow oil that was stored in the freezer. Yield: 4.72 g, 96%. <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>, TMS ref.): 8.38 (s, 1 H, N=CHPh), 7.76 (m, 2 H), 7.44 (m, 3 H), 4.46 (dd, 1 H, J=4.9, J=8.8), 4.16 (m, 10 H), 2.7-2.3 (m, 3 H), 1.32 (m, 15 H). <sup>13</sup>C NMR (250 MHz, CDCl<sub>3</sub>): 171.08, 165.47, 135.54, 131.18, 128.49, 128.44, 69.81 (dd, J=4.4, J=10.5), 62.5 (m), 61.11, 32.73 (t, J=133.1), 28.83, 16.30 (d, 3JC-P=24.3), 14.05 ppm. <sup>31</sup>P NMR (250 MHz, CDCl<sub>3</sub>): 23.66, 23.93 ppm, downfield from H<sub>3</sub>PO<sub>4</sub>. IR (neat): 2984 (C-H), 2933 (C-H), 2907 (C-H), 2872 (C-H), 1737 (ester C=O), 1641 (CH=N), 1280 (shoulder; P=O), 1253 (P=O), 1027 (C-O), 970 (P-C-P), 754 cm<sup>-1</sup> (P-O).

Ethyl 2-Amino-4,4-bis(diethoxyphosphoryl)butyrate

In a typical synthesis, ethyl N-benzylidene-2-amino-4,4-bis(diethoxyphosphoryl)butyrate (3.00 g, 6.1 mmol) was dissolved in 10 mL DI H<sub>2</sub>O at room temperature. p-Toluenesulfonic acid monohydrate (1.74 g, 9.2 mmol) was then added and the mixture was stirred for 30 min. at room temperature. After extraction with Et<sub>2</sub>O (4 x 15 mL) to remove benzaldehyde, the aqueous solution was rendered alkaline by addition of saturated aqueous NaHCO<sub>3</sub> (ca. pH 8.1) and then extracted with CHCl<sub>3</sub> (4 x 10 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered and evaporated under reduced pressure to give a light yellow oil that was used without further purification. The compound was stored in the freezer and checked by NMR to ascertain purity before each use. Yield: 2.3 g, 94%. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>, TMS ref.): 4.2 (m, 10 H), 3.77 (dd, J=4.4, J=10.6, 1 H), 3.14-2.84 (dddd, 3JHH=3.3, 3J'HH=8.9, 2JHP=23.2, and 2J'HP=24.7 Hz, 1 H, PCHP), 2.5-2.2 (m, 1 H), 2.1-1.8 (m, 1 H), 1.3 ppm (m, 15 H). <sup>13</sup>C NMR (200 MHz, CDCl<sub>3</sub>): 175.50, 62.5

(m), 61.02, 52.77 (dd,  $J=10.3$ ,  $J=3.1$ ), 32.77 (t,  $J=133.9$ ), 30.49, 16.39 (d,  $J=6.1$ ), 14.22 ppm.  $^{31}\text{P}$  NMR (250 MHz,  $\text{CDCl}_3$ ): 24.43, 24.16 ppm, downfield from  $\text{H}_3\text{PO}_4$ . IR (neat): 3476 (br, N-H), 2984 (C-H), 2934 (C-H), 2910 (C-H), 1733 (ester C=O), 1646 ( $\text{NH}_2$  deformation), 1277 (shoulder, P=O), 1245 (P=O), 1020 (C-O), 972 (P-C-P), 838 (P-O), 799 cm<sup>-1</sup> (P-O).

Ethyl 4,4 - bis(diethoxyphosphoryl) - 2 - (1,2 - dihydro - 1,2 - methanofullerene[60] - 61 - carboxamido)butyrate,  $\text{C}_{60}\text{AMBP}$  - protected

$\text{C}_{60}\text{-CHCOOH}$  (0.100 g, 0.128 mmol) and 1-hydroxybenzotriazole, BtOH, (0.035 g, 0.256 mmol) were combined in 30 mL PhBr. Approximately 0.104 g (0.256 mmol) ethyl 2-amino-4,4-bis(diethoxyphosphoryl)butyrate, AMBP, was added via pipette. Immediately, 0.0530 g (0.256 mmol) 1,3-dicyclohexyl-carbodiimide (DCC) was added to the reaction flask. Stirring for 5 d at room temperature under inert atmosphere yielded a dark cranberry colored solution. The product was purified by column chromatography on a 10x1 in.  $\text{SiO}_2$  column using toluene to elute PhBr and a 1% MeOH/ $\text{CHCl}_3$  solution to elute the cranberry colored product. Two precipitations from  $\text{CHCl}_3$  with  $\text{Et}_2\text{O}$  gave a brown solid that was collected in a centrifuge tube and dried overnight under vacuum at room temperature. Yield: 0.103 g, 69%.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ): 8.93 (br d, 1H,  $J=7.8$ ), 4.85 (m, 1 H), 4.79 (s, 1H), 4.27 (m, 10 H), 2.71–2.46 (m, 3H), 1.43 ppm (m, 15 H).  $^{13}\text{C}$  NMR (200 MHz,  $\text{CDCl}_3$ ): 170.74, 165.37, 34 out of 60 fullerene resonances observed – 148.53, 148.36, 146.48, 146.17, 145.59, 145.50, 145.08, 144.89, 144.80, 144.61, 144.43, 144.31, 144.24, 144.02, 143.76, 143.70, 143.49, 143.44, 143.10, 142.86, 142.77, 142.72, 142.55, 142.24, 141.98, 141.91, 141.85, 140.87, 140.58, 140.20, 140.10, 136.20, 136.10, 71.56 (2x;  $\text{sp}^3$   $\text{C}_{60}$  bridgehead carbon atoms), 63.33 (m), 61.93, 53.13, 41.11, 33.34 (t,  $J=132.1$  Hz), 26.72 (br s), 16.48 (br d), 14.23 ppm.  $^{31}\text{P}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\text{H}_3\text{PO}_4$ ): 24.51 (d,  $J=5.2$  Hz), 24.48 ppm downfield from  $\text{H}_3\text{PO}_4$  (d,  $J=5.2$  Hz). IR (KBr): 3244 (N-H), 2977 (C-H), 2900 (C-H), 1734 (carboxy ester C=O), 1684 (amide I band), 1540 (amide II band), 1249 (P=O),

1023 (C-O), 972 (P-C-P), 798 (P-O) 528 cm<sup>-1</sup> (fullerene stretch). UV-vis (CHCl<sub>3</sub>, λ nm, (ε M<sup>-1</sup> cm<sup>-1</sup>)): 326 (3.4 x 10<sup>4</sup>), 402 (4.1 x 10<sup>3</sup>), 416 (3.4 x 10<sup>3</sup>), 427 (3.7 x 10<sup>3</sup>), 479 (1.7 x 10<sup>3</sup>), 690 (2.1 x 10<sup>2</sup>). High res. APCI-MS (50:50 CHCl<sub>3</sub>/MeOH): 1164.153200 (M+ + 1).  
 Anal Calc. for C<sub>76</sub>H<sub>31</sub>NO<sub>9</sub>P<sub>2</sub>: C, 78.42; H, 2.68; N, 1.20; O, 12.37; P, 5.32. Found: C,  
 5 77.42; H, 3.19; N, 1.19; (O, 12.89); P, 5.31.

4,4 - bisphosphono - 2 - (1,2 - dihydro - 1,2 - methanofullerene[60] - 61 - carboxamido)butyric acid, C<sub>60</sub>AMBP

C<sub>60</sub>-AMBP-protected as described above (0.160 g, 0.137 mmol) was dissolved in  
 10 125 mL anhydrous toluene in a glove box. I-Si(CH<sub>3</sub>)<sub>3</sub> (0.196 mL, 0.275 g, 1.37 mmol) was  
 added drop-wise at room temperature over 30 seconds. After 72 hours stirring at 50 °C, the  
 reaction was filtered to remove a dark insoluble product. The filtrate was then removed  
 from the glove box and quenched with 1 mL MeOH. An insoluble brown precipitate  
 formed immediately. It was collected in a centrifuge tube, washed consecutively with  
 15 CHCl<sub>3</sub> and Et<sub>2</sub>O, and then dried under vacuum at 65 °C for 8 hours. This compound was  
 insoluble in all common solvents. Yield: 127 mg, 90%. IR (KBr): 3600-2500 (br, P-OH),  
 2923 (C-H), 1719 (Acid C=O), 1650 (amide I band), 1540 (amide II band), 1241-1024  
 (envelope P=O, C-O, OH bend), 928 (P-C-P), 526 cm<sup>-1</sup> (fullerene resonance).

The intermediate tetra-silyl ester, produced by the reaction of ITMS with the four  
 20 phosphonate ester groups was characterized by <sup>1</sup>H NMR. <sup>1</sup>H NMR (200 MHz, CD<sub>2</sub>Cl<sub>2</sub>):  
 NH not observed, 5.26 (s, 1 H), 5.04 (m, 1 H), 4.37 (q, 2 H), 2.75-2.15 (br m, 3 H), 1.35 (t,  
 3 H), 0.52 and 0.43 (br s, 36 H). CH<sub>3</sub>CH<sub>2</sub>I is also present in the sample as a by-product of  
 the deprotection reaction.

4,4-bisphosphono-2-(polyhydroxyl-1,2-dihydro-1,2-methanofullerene[60]-61-  
 25 carboxamido)butyric acid, C<sub>60</sub>(OH)<sub>16</sub>AMBP

C<sub>60</sub>AMBP as described above (0.050 g, 0.05 mmol) was dissolved in 0.5 mL 40%  
 tetra n-butylammonium hydroxide and then diluted to 10 mL with 1 M KOH. The mixture

was stirred for 24 h at room temperature and then chromatographed on Sephadex G-25 (fine) size exclusion gel (2.5" x 5"). The product eluted as a well-defined brown-orange band followed later by a volume of colorless basic eluent. Between aliquots, the column was rinsed thoroughly with DI H<sub>2</sub>O until the pH of the eluent was no longer basic. After  
5 three passes, the pH of the collected sample fractions was ca. 6, suggesting that most of the base had been removed. The collected fractions were reduced to 10 mL under vacuum with very gentle heating (T<30 °C) and then dried under slow air flow overnight to remove the remaining solvent. The resulting flaky, black solid was collected and dried at 100 °C/1 torr over P<sub>2</sub>O<sub>5</sub> for 12 hours. 37 mg C<sub>60</sub>(OH)<sub>16</sub>AMBP isolated. <sup>1</sup>H NMR (250 MHz, D<sub>2</sub>O):  
10 4.15, 3.95, 3.56, 2.25, 1.9-0.9 ppm (all br signals). <sup>31</sup>P NMR (250 MHz, D<sub>2</sub>O): 12.4 ppm upfield from H<sub>3</sub>PO<sub>4</sub> (br weak singlet). IR (KBr): 3358 (v br, O-H), 2922 (aliphatic C-H), 1717 (shoulder, carboxy C=O), 1595 (v br, amide C=O), 1387 (v br, O-H bend), 1239 (P=O), 1072 (s, C-O), 1045 (s, C-O). UV-vis (H<sub>2</sub>O): No maxima were observed; the absorption curve decreases gradually toward the visible region. To describe the absorption  
15 strength, measurements were taken at 300, 400, and 500 nm. The molar extinction coefficients at these wavelengths are 22.9 x 10<sup>6</sup>, 7.57 x 10<sup>6</sup> and 2.08 x 10<sup>6</sup> cm<sup>2</sup>/mol, respectively. MALDI-MS: no peaks observed other than 720 (C<sub>60</sub>). Anal. Calc. for C<sub>66</sub>H<sub>27</sub>NO<sub>25</sub>P<sub>2</sub> (C<sub>60</sub>(OH)<sub>16</sub>AMBP) C, 61.18; H, 2.10; N, 1.09; P, 4.78; O, 30.87 found: C, 60.38; H, 2.77; N, 1.27; P, 4.86; (O, 30.72 by difference). Analysis for potassium showed  
20 only a trace amount (<0.37%). This product, C<sub>60</sub>(OH)<sub>16</sub>AMBP, is one of two bone-targeted fullerenes tested in this Example.

Fullerenol[60], C<sub>60</sub>(OH)<sub>30</sub> · 2 H<sub>2</sub>O

In a typical fullerenol synthesis, 20 mg (2.7 x 10<sup>-5</sup> mol) C<sub>60</sub> (99.5%) was dissolved in a minimal volume of toluene (ca. 20 mL), using sonication to encourage dissolution.  
25 This solution was then stirred vigorously with 10 mL concentrated KOH (ca. 1 g/mL) and

three drops tetra-n-butylammonium-hydroxide (TBAH) phase transfer catalyst. Decoloration of the toluene layer occurred within minutes accompanied by formation of a black semi-solid at the solvent interface. The toluene layer was carefully decanted and the remaining water layer was sonicated briefly and then stirred under air sparge at room temperature for 10-12 hours to allow further reaction and to remove remaining toluene. Deionized water was then added to the remaining solution or solid to bring the total volume to 25 mL. The resulting suspension was stirred for 24-48 hours to ensure complete reaction. The resulting orange-brown solution was diluted with an additional 10 mL DI H<sub>2</sub>O and then vacuum filtered through celite on a Büchner funnel to remove a small amount of insoluble material. The filtrate was concentrated under reduced pressure with gentle warming until precipitate started to form. MeOH was then added to complete precipitation. A mixture of brown and white solids was collected by centrifugation. The solids were redissolved in a minimal amount of water and again precipitated with MeOH to remove additional KOH and TBAH impurities. This step was repeated a third time. After the final precipitation, the compound was chromatographed on Sephadex G-25 (fine) size-exclusion gel. Two bands were observed: the first broad, orange band was collected while the second brown-orange band, being strongly basic, was discarded. The collected eluent was concentrated and precipitated with MeOH. If a pH measurement of the mother liquor indicated presence of base (if the pH > 6 when saturated with CO<sub>2</sub>), the compound was further purified. UV-vis: No maxima were observed; the absorption curve decreases gradually toward the visible region. To describe the absorption strength, measurements were taken at 300, 400, and 500 nm. The molar extinction coefficients at these wavelengths are  $29.3 \times 10^6$ ,  $9.7 \times 10^6$  and  $2.6 \times 10^6$  cm<sup>2</sup>/mol, respectively. Anal Calc. for C<sub>60</sub>H<sub>30</sub>O<sub>30</sub>  $\times$  2 H<sub>2</sub>O, (C<sub>60</sub>(OH)<sub>30</sub>  $\times$  2 H<sub>2</sub>O) C, 56.88; H, 2.71; O, 40.41. Found: C, 56.54; H, 2.53; O,

40.93 by difference). This product,  $C_{60}(OH)_{30}$ , is the second of two bone-targeted fullerenes tested in this Example.

### Results And Discussion

Constant composition growth experiments were first performed in pure  
5 supersaturated solutions of HAP and then in the presence of  $C_{60}(OH)_{16}AMBP$  and  $C_{60}(OH)_{30}$ . The results are presented in Table 1.

Table 1

$C_{60}(OH)_{30}$ / $10^{-6}$ mol L <sup>-1</sup>	Rate / $10^{-8}$ mol min <sup>-1</sup> m <sup>-2</sup>	$C_{60}(OH)_{16}AMBP$ / $10^{-6}$ mol L <sup>-1</sup>	Rate / $10^{-8}$ mol min <sup>-1</sup> m <sup>-2</sup>
0	9.09	0	9.09
0.41	8.31	0.39	7.67
0.81	7.8	0.77	6.51
1.22	6.55	1.16	4.55
1.63	5.94	1.54	3.77
2.03	5.7	1.93	2.83
2.44	4.65	2.32	2.46
2.85	4.07	2.7	1.92
3.25	3.97	3.09	1.57
3.66	3.85	3.47	1.23
4.07	2.64		
4.47	2.49		

Figures 5 and 6 show typical plots of titrant volume required to maintain the  
10 supersaturation as a function of time at different fullerene concentrations for  $C_{60}(OH)_{30}$  and  $C_{60}(OH)_{16}AMBP$ , respectively. For comparison, a curve of titrant consumption for the growth of HAP crystals in pure supersaturated solutions is included in each plot (open symbols). All the rate curves show a rapid titrant addition immediately following the introduction of seed crystals. This frequently observed phenomenon, usually attributed to  
15 conditioning of the surface of the seed crystals in the supersaturated solution, may reflect ion exchange involving solution and surface cations and protons, or the removal of active growth sites on the seed crystals due to the rapid crystallization of high energy sites. Significant reductions of the initial surges observed in the presence of the fullerenes suggest

their adsorption at the growth sites on the HAP seed crystals, thus their competition with other initial surface processes. It can be seen in Figure 5 that linearity of the rate plots of HAP crystal growth (reflected by the constant slopes of volume versus time curves) was usually achieved 10 - 20 minutes after seed introduction to the supersaturated solution in experiments performed in the absence and presence of fullerenes. It should be noted that at high concentrations of inhibitors, HAP crystals appear to grow only during the initial reaction stage.

It is quite well established that strong inhibitors of crystal growth, such as the phosphonates, act by blocking, through adsorption, active growth sites at the crystal surfaces. Commonly, inhibition kinetics data are interpreted in terms of a simple Langmuir adsorption model. Assuming that the adsorbed fullerene molecules occupy a fraction,  $\theta$ , of the active growth sites, thereby preventing them from participating in the growth, the growth rate  $R$  can be written in terms of the uninhibited rate  $R_0$  (Eq. (2)):

$$R_0/R = 1 + KLC \quad (2)$$

in which  $KL$  is the adsorption affinity constant with units of liters per mole. HAP crystal growth rates  $R$  measured in the presence of  $C_{60}(OH)_{30}$  and  $C_{60}(OH)_{16}AMBP$  are plotted in Figure 7 as a function of additive concentration.

Comparison of the two curves shows that both compounds inhibit HAP crystal growth, with  $C_{60}(OH)_{16}AMBP$  being the more effective inhibitor. At a concentration of  $3.1 \times 10^{-5}$  M,  $C_{60}(OH)_{30}$  reduces the HAP crystal growth by 58%, while  $C_{60}(OH)_{16}AMBP$  reduces the rate by 87%. The increase in inhibition is linear with concentration for  $C_{60}(OH)_{30}$ , but not for the bisphosphonate derivative,  $C_{60}(OH)_{16}AMBP$ .

Following Eq. (2), plots of  $R_0/R$  as a function of concentration for each compound are shown below in Figure 8. The linear relation shown for  $C_{60}(OH)_{30}$  indicates that the compound inhibits HAP crystal growth by the mechanism described by the Langmuir

formalism. From the slope, the affinity constant is  $4.14 \times 10^5 \text{ L mol}^{-1}$  ( $R^2 = 0.97$ ). In fact, this affinity of fulleranol materials for HAP has also been observed previously in an in vivo mouse model study using radiolabeled  $^{166}\text{Ho}@C_{60}(\text{OH})_x$ .

The plot in Figure 8 of  $R_0/R$  versus concentration for  $C_{60}(\text{OH})_{16}\text{AMBP}$  lacks  
5 linearity, which suggests that the mechanism of inhibition is different from that described by the Langmuir model. The model relies on the assumptions that the inhibitor reversibly binds to the mineral surface at active growth sites and that the surface-bound molecules do not interact with one another. For  $C_{60}(\text{OH})_{16}\text{AMBP}$ , these assumptions may be invalid. The curvature observed in Figure 7 for  $C_{60}(\text{OH})_{16}\text{AMBP}$  at higher concentrations may be  
10 caused by lateral interference among the surface-bound molecules. Once adsorbed to a surface, molecules are capable of lateral movement and surface aggregation. Under such conditions, an equilibrium distribution may be impossible, thereby preventing the molecules from effectively inhibiting mineralization. In experiments with higher inhibitor concentrations, molecular aggregation can develop more easily, thus making the decrease  
15 in inhibitory activity more apparent. Such aggregation may result from enhanced intermolecular hydrogen bonding interactions among the hydroxyl and carboxylic and phosphonic acid groups of the fullerene material.

Table 2 compares the percent reductions in growth rate of the two fulleranol derivatives to that for 1-hydroxyethylidene-1,1-diphosphonic acid,  
20  $\text{CH}_3\text{C}(\text{OH})[\text{P}(\text{O})(\text{OH})_2]_2$ , a commercially-available bone-vectored compound used in the treatment of osteoporosis. At  $1.0 \times 10^{-6} \text{ M}$  inhibitor concentration, neither  $C_{60}(\text{OH})_{30}$  nor  $C_{60}(\text{OH})_{16}\text{AMBP}$  is as effective as  $\text{CH}_3\text{C}(\text{OH})[\text{P}(\text{O})(\text{OH})_2]_2$  at inhibiting HAP crystal growth.  $C_{60}(\text{OH})_{30}$  also has a lower affinity constant, suggesting that the compound binds to the surface less strongly than  $\text{CH}_3\text{C}(\text{OH})[\text{P}(\text{O})(\text{OH})_2]_2$ . The lower binding constant for  
25  $C_{60}(\text{OH})_{30}$  is not surprising given that the fulleranol does not contain a bisphosphonic acid

moiety. The hydroxyl functionalities present in  $C_{60}(OH)_{30}$  are capable of hydrogen bonding to the surface, but they do not provide the stronger ionic interactions that are present with bisphosphonic acid groups.

Table 2

Compound	Concentration mol/L	Percent Reduction in Growth Rate	Affinity Constant $L\ mol^{-1}$
$C_{60}(OH)_{30}$	$1.0 \times 10^{-6}$	28	$4.14 \times 10^5$
$C_{60}(OH)_{16}AMBP$	$1.0 \times 10^{-6}$	50	-
$C_{60}(OH)_{16}AMBP$	$3.5 \times 10^{-6}$	87	-
$CH_3C(OH)[P(O)(OH)_2]_2$	$1.0 \times 10^{-6}$	69 <sup>ref 29</sup>	$13.3 \times 10^5$ <sup>ref 29</sup>

5

13.3 Comparison of  $C_{60}(OH)_{16}AMBP$  to  $CH_3C(OH)[P(O)(OH)_2]_2$  is somewhat problematic because the latter molecule inhibits HAP crystal growth by a mechanism that appears strictly Langmuirian, with the affinity constant being independent of concentration. As shown in Figure 7, such independence is not the case for

10  $C_{60}(OH)_{16}AMBP$ .

Despite uncertainty in the inhibition mechanism, the results demonstrate that both  $C_{60}(OH)_{30}$  and  $C_{60}(OH)_{16}AMBP$  inhibit HAP crystal growth from supersaturated calcium phosphate solutions and that both compounds have relatively strong affinities for HAP. The greater crystal growth inhibition by  $C_{60}(OH)_{16}AMBP$  stresses the importance of

15 incorporating bisphosphonate moieties into bone-vectored fullerene derivatives. Further explanation for the diminished rate inhibition observed at higher  $C_{60}(OH)_{16}AMBP$  concentrations will require studies of other fullerene compounds, especially those having multi-directional surface-binding functionalities such as  $C_{60}C_6(COOH)_{12}$  and others. As the first investigation, however, the present study demonstrates the potential usefulness of

20 fullerene-based materials in tissue-targeting technologies and lays the ground-work for *in vivo* studies using radiolabeled bisphosphonate materials as potential bone therapeutic

agents that effectively target bone and are likely to be effective for reducing the rate of bone loss.

#### Fluorination

When one or more fluorine ions are bound to the bone-vectored fullerene disclosed  
5 above, the result is a bimodal agent having both bone-targeting and bone growth ligands. It is preferred that a suitable molecular template be used during production of the bimodal agent, so that the ligands are bound in opposing positions on the fullerene. If the ligands are too close together, the effectiveness of one or both may be reduced.

Fluorine atoms can be affixed to the fullerene by any suitable method, including  
10 exposing the fullerene soot to a fluorine gas at a pressure of several hundred Torr, and including the methods and techniques disclosed in U.S. Patents No. 5,558,903 and 5,958,523, both of which are incorporated herein by reference. It is believed that the number of fluorine atoms that can be affixed to the present bisphosphonated fullerenes so as to achieve optimal bone growth stimulation is between 1 and 20.

15 The present invention provides advantages over previously known bisphosphonated bone therapeutic agents, in that it allows both an anti-resorption agent and a growth agent to be placed in proximity to active bone sites and does so without interfering with other biological mechanisms and without risk of toxicity.

While the present invention has been disclosed and described in terms of a  
20 preferred embodiment, the invention is not limited to the preferred embodiment. For example, while the present invention has been described for use in bone, it should be understood that the target tissue may be any suitable material containing hydroxyapatite, such as teeth. In addition, various modifications to the ligands and the scaffolding, or carrier, and the arrangement of the ligands on the scaffolding can be made without  
25 departing from the scope of the invention. In the claims that follow, any recitation of steps

is not intended as a requirement that the steps be performed sequentially, or that one step be completed before another step is begun, unless explicitly so stated.

## CLAIMS

What is claimed is:

1. A therapeutic composition targeted to diseased or injured bone comprising:  
a biologically inert carrier;  
5 a bone vector chemically bonded to the carrier; and  
a therapeutic agent chemically bonded to the carrier;
2. The composition of claim 1 wherein the bone vector comprises a bisphosphonate.
3. The composition of claim 1 wherein the carrier comprises a fullerene.
4. The composition of claim 1 wherein the carrier is C<sub>60</sub>.
- 10 5. The composition of claim 1 wherein the carrier is C<sub>60</sub> and the bone vector comprises a bisphosphonate.
6. The composition of claim 1 wherein the carrier is C<sub>60</sub>(OH)<sub>16</sub>.
7. The composition of claim 1 wherein the therapeutic agent comprises fluoride.
8. A method for providing bone therapy in a patient in need of bone therapy  
15 comprising administering to said patient a pharmaceutically effective amount of a  
compound comprising a biologically inert carrier, a bone vector; and a therapeutic agent.
9. The method of claim 8 wherein the bone vector comprises a bisphosphonate.
10. The method of claim 8 wherein the carrier comprises a fullerene.
11. The method of claim 8 wherein the carrier is C<sub>60</sub>.
- 20 12. The method of claim 8 wherein the therapeutic agent comprises fluoride.
13. The composition of claim 8 wherein the carrier is C<sub>60</sub> and the bone vector comprises a bisphosphonate.
14. A method of making a bone therapeutic agent, comprising:  
providing a biologically inert carrier;  
25 bonding a bone targeting agent to the carrier;

bonding a bone growth agent to the carrier.

- 15     The method of claim 14 wherein the bone targeting agent comprises a bisphosphonate.
16.     The method of claim 14 wherein the carrier comprises a fullerene.
- 5     17.     The method of claim 14 wherein the carrier is C<sub>60</sub>.
18.     The method of claim 14 wherein the therapeutic agent comprises fluoride.
19.     The composition of claim 14 wherein the carrier is C<sub>60</sub> and the targeting agent comprises a bisphosphonate.
20.     A method for providing bone therapy in a patient in need of bone therapy
- 10     comprising administering to said patient a pharmaceutically effective amount of a compound comprising 4,4-bisphosphono-2-(polyhydroxyl-1,2-dihydro-1,2-methanofullerene[60]-61-carboxamido)butyric acid.




Figure 1




Figure 2




Fig. 3




Figure 4




Fig. 5




Fig. 6




Fig. 7





Fig. 8

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/13445

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) :A61K 47/00 US CL : 514/769 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/769  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, CAPLUS, USPATFUL, PCTFUL search terms: fullerene, C60(OH)16, bone, bisphosphonate, fluoride, bone, resorption		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database Caplus on STN, Accession No.2000:736385, PEETERS et al., 'Synthesis, Photophysical Properties, and Photovoltaic Devices of Oligo(p0phenylene vinylene)-fullerene Dyads', abstract, J. Phys. Chem. B., 2000, Vol. 104(440, Pages 10174-10190.	1-20
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* "A" "E" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "G" document member of the same patent family
Date of the actual completion of the international search 12 JUNE 2001		Date of mailing of the international search report 14 AUG 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3930		Authorized officer VICKIE KIM  Telephone No. (703) 308-1235

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**